Evropska unija - slovenščina - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanediol monohidrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - zdravila, ki se uporabljajo pri diabetesu - qtern, fiksni odmerek kombinacija saxagliptin in dapagliflozin, je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzor, ko metforminom in/ali sulfonil sečnine (su) in eden od monocomponents od qtern ne zagotavljajo ustrezne glycaemic nadzor,ko se že zdravijo z brezplačno kombinacija dapagliflozin in saxagliptin. (glej točki 4. 2, 4. 4, 4. 5 in 5. 1, če so na voljo podatki o kombinacije študiral.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab  - metformin hidroklorid, saxagliptin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze je navedena kot dodatek k prehrane in vadbe za izboljšanje glycaemic nadzor pri odraslih bolnikih, starih 18 let in starejši s sladkorno boleznijo tipa 2 neustrezno nadzorovano na njihovo maksimalno odmerkom metformin sam ali tiste, ki že zdraviti s kombinacijo saxagliptin in metformin kot ločene tablet. komboglyze je prikazano tudi v kombinaciji z insulin (i. trojna kombinacija terapija), kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor pri odraslih bolnikih, starih 18 let in starejših s tipa 2 sladkorna bolezen, ko inzulin in metforminom sam ne zagotavljajo ustrezne glycaemic nadzor.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - metformin hidroklorid, saxagliptin, dapagliflozin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - qtrilmet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzora, ko je z metforminom ali brez sulfonil sečnine (su) in bodisi saxagliptin ali dapagliflozin ne zagotavlja primerne glycaemic nadzor. ko se že zdravijo z metforminom in saxagliptin in dapagliflozin.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - sitagliptin - filmsko obložena tableta - sitagliptin 50 mg / 1 tableta - sitagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - sitagliptin - filmsko obložena tableta - sitagliptin 100 mg / 1 tableta - sitagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - sitagliptin - filmsko obložena tableta - sitagliptin 25 mg / 1 tableta - sitagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sitagliptin - filmsko obložena tableta - sitagliptin 100 mg / 1 tableta - sitagliptin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sitagliptin - filmsko obložena tableta - sitagliptin 50 mg / 1 tableta - sitagliptin

Evropska unija - slovenščina - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , trojna kombinacija terapija), kot dodatek k prehrani in vadbi pri bolnikih neustrezno nadzorovano na maksimalno dopustne odmerek metforminom in sulfonil sečnine. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.